| First Author | Arunachalam S | Year | 2013 |
| Journal | FEBS Lett | Volume | 587 |
| Issue | 2 | Pages | 105-10 |
| PubMed ID | 23219922 | Mgi Jnum | J:192556 |
| Mgi Id | MGI:5465372 | Doi | 10.1016/j.febslet.2012.11.019 |
| Citation | Arunachalam S, et al. (2013) Doxorubicin treatment inhibits PPARgamma and may induce lipotoxicity by mimicking a type 2 diabetes-like condition in rodent models. FEBS Lett 587(2):105-10 |
| abstractText | Doxorubicin-treated animals show elevated serum triglyceride and blood glucose levels. Adipocytes play an important role in buffering blood glucose and lipids. A raise in serum lipid level triggers adipogenesis in order to increase the lipid absorption capacity of adipose tissue. Doxorubicin inhibits adipogenesis through the down-regulation of PPARgamma, a crucial component of the lipid metabolic pathway which controls the expression of glucose and fatty acid transporters. Doxorubicin-mediated down-regulation of PPARgamma inhibits blood glucose and lipid clearance thereby causing hyperglycemia and hyperlipidemia resulting in lipotoxicity, glucotoxicity, inflammation and insulin resistance. Therefore we hypothesize that doxorubicin treatment could mimic a type 2 diabetic condition. |
